表紙
市場調查報告書

Liquid biopsy (液體活檢) 的市場預測□分析 (2020-2024年) :Covid-19大流行影響下□癌症類型□使用類型□給執行者與顧問者的守則

Liquid Biopsy Markets by Cancer Type and by Usage Type with Impact of Covid-19 Pandemic. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2020-2024

出版商 Howe Sound Research 商品編碼 939948
出版日期 內容資訊 英文 385 Pages
商品交期: 最快1-2個工作天內
價格
Liquid biopsy (液體活檢) 的市場預測□分析 (2020-2024年) :Covid-19大流行影響下□癌症類型□使用類型□給執行者與顧問者的守則 Liquid Biopsy Markets by Cancer Type and by Usage Type with Impact of Covid-19 Pandemic. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2020-2024
出版日期: 2020年06月03日內容資訊: 英文 385 Pages
簡介

使用體外血液測試識別癌症DNA的方式正興起了癌症檢查的革命。此技術是以血液測試出各種種類與範圍的癌症,創造了篩檢的可能性。新興公司的GRAIL公司已經發表了一次的血液檢查就可以篩檢出各種癌症的方法。這公司致力於早期發現癌症的方式,在循環無細胞基因組圖譜(CCGA)領域已經有超過10,000以上的人接受測試。

本報告是以全球的液體活檢市場調查為主,包含國家、癌症的種類、不同用途的市場分析與預測、近年的開發動向、主要相關企業的介紹等,提供完整有系統的資訊與分析。

第1章 導論與市場定義

  • 液體活檢是?
  • 測序革命
  • 市場定義
  • 調查方式
  • 液體活檢關連支出預估

第2章 市場概要

  • 動態市場與相關企業
  • 活檢的使用
    • 癌症
    • 癌前狀況
    • 炎症狀態
  • 活檢部位
  • 現狀:活檢分析
  • 癌症證據:液體活檢技術
  • 圍困中的癌症治療方案
  • 業界構成

第3章 市場動向

  • 促進成長因素
    • 非侵入式的方式改變遊戲規則
    • 低成本
    • 高精準度
    • 潛在應用範圍廣大
    • 人口高齡化
  • 不利成長因素
    • 低價格
    • 缺少統一的標準
    • 協議阻力
    • 前期成本
    • COVID-19
  • 機器與自動化
  • 開發診斷技術

第4章 液體活檢的最新發展趨勢

  • 最新發展趨勢:重要性□本章節的使用方式

第5章 主要企業介紹

  • Abbott Diagnostics
  • AccuraGen Inc
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Molecular MD
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Oxford Nanopore Technologies
  • Perkin Elmer
  • Personal Genome Diagnostics
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Quidel
  • Rarecells SAS
  • RareCyte
  • Resolution Biosciences, Inc
  • Roche Molecular Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SRI International
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Trovagene
  • Volition

第6章 液體活檢的全球市場

  • 全球市場的概要:以國別區分
  • 全球市場的概要:以癌症種類區分
  • 全球市場的概要:以用途區分

第7章 液體活檢的全球市場:以癌症種類區分

  • 乳癌
  • 大腸癌
  • 子宮頸癌
  • 肺癌
  • 前列腺癌
  • 其他癌症

第8章 全球市場的概要:以用途區分

  • 排序
  • 診斷
  • 治療
  • 監控

附錄

目錄

OVERVIEW:

The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? This report provides detailed analysis.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread SCREENING FOR ALL TYPES OF CANCERS WITH A BLOOD TEST.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has JUST MOVED OUT OF THE DEVELOPMENT PHASE AND INTO THE GROWTH PHASE. The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Liquid Biopsy Market - Strategic Situation Analysis & Impact of COVID-19

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What is Liquid Biopsy?
  • 1.2 The Sequencing Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Liquid Biopsy
    • 1.5.1 An Historical Look at Clinical Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Genomic Instrumentation Supplier
      • 2.1.3.1 Cell Separation and Viewing Instrumentation Supplier
    • 2.1.4 Pharmaceutical/Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Lab
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Using Biopsies
    • 2.2.1 Cancer
    • 2.2.2 Precancerous conditions
    • 2.2.3 Inflammatory conditions
  • 2.3 Biopsy Sites
  • 2.4 The Situation Today - Biopsy Analysis
  • 2.5 Evidence of Cancer - Liquid Biopsy Technology
    • 2.5.1 The Big Picture on Liquid Biopsy Technology
    • 2.5.2 The Role of CTCs
      • 2.5.2.1 Types of CTCs
      • 2.5.2.2 CellSearch Detection- Ultimate Sensitivity
      • 2.5.2.3 Epic Sciences Detection- Imaging Takes the Lead
      • 2.5.2.4 Maintrac Detection - The Microscope
      • 2.5.2.5 Other Methods
    • 2.5.3 ctDNA - Going Mainstream?
    • 2.5.4 Exosomes and Micro Vesicles - New Kid on the Block
    • 2.5.5 The Multiple Play
  • 2.6 Cancer Treatment Protocol Under Siege
    • 2.6.1 Issues to Liquid Biopsy Adoption - Double Diagnostics
    • 2.6.2 The Cancer Screening Market Opportunity
      • 2.6.2.1 GRAIL - What Is It?
    • 2.6.3 Cancer Management vs. Diagnosis
      • 2.6.3.1 The Role of Risk Assessment
      • 2.6.3.2 Managing Therapy
      • 2.6.3.3 Monitoring Disease - What Is It?
    • 2.6.4 Phases of Adoption - Looking into The Future
    • 2.6.5 The Promise of Liquid Biopsy
  • 2.7 Structure of Industry Plays a Part
    • 2.7.1 Hospital Testing Share
    • 2.7.2 Economies of Scale
      • 2.7.2.1 Hospital vs. Central Lab
    • 2.7.3 Physician Office Lab's
    • 2.7.4 Physician's and POCT

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Non Invasive Game Changer
    • 3.1.2 Lower Cost
    • 3.1.3 Greater Accuracy
    • 3.1.4 Wide Range of Potential Uses
    • 3.1.5 Aging Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 Lower prices
    • 3.2.2 Lack of Standards
    • 3.2.3 Protocol Resistance
    • 3.2.4 Initial Adoption Cost
    • 3.2.5 COVID-19
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution
    • 3.4.2 Impact of NGS on pricing
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 CGES Testing, A Brave New World
    • 3.4.5 Biochips/Giant magneto resistance based assay

4. Liquid Biopsy Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
      • Liquid Biopsy Shows Promise as Screen for Cancers
      • Inivata launches RaDaR™ for the detection of residual disease and recurrence
      • Liquid Biopsy Assay Detects 50+ Types of Cancer
      • Liquid Biopsy Study Confirms Concordance with Tissue Biopsy
      • Guardant Health Liquid Biopsy Expands Medicare Coverage
      • Aethlon Medical Lands Grant for Exosome Isolation Device
      • Biolidics to Develop Liquid Biopsy Breast Cancer Test
      • Liquid Biopsy Equal to Tissue to Indicate Immunotherapy Response
      • Exact Sciences buys Genomic Health
      • Multi-Gene Liquid Biopsy Breast Cancer Panel
      • Bio-Techne receives FDA breakthrough device for prostate cancer liquid biopsy
      • Thrive to Develop Earlier Detection of Multiple Cancer Types
      • Guardant Health Liquid Biopsy Test to be Covered by EviCore
      • Liquid biopsy combines Illumina's 'ultradeep' sequencing with Grail's machine learning
      • Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
      • Natera Commercializes Tumor Whole Exome Sequencing from Plasma
      • Sienna Buys Liquid Biopsy & Exosome Isolation Technology
      • Inivata Completes £39.8M Series B Funding Round
      • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
      • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials
      • Biodesix Acquires Integrated Diagnostics
      • Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx
      • Bio-Techne to Acquire Exosome Dx for Up to $575M
      • GRAIL Announces Data on Detection of Early-Stage Lung Cancers
      • Precision for Medicine Acquires ApoCell
      • NeoGenomics to Acquire Genoptix for Cash, Stocks
      • PGDx Liquid Biopsy Assay to be Used in Cancer Drug Study
      • Liquid Biopsy IDs More NSCLC Mutations in Study of Guardant Test
      • Inivata Gets Draft Medicare Coverage Determination for Lung Cancer Test

5. Profiles of Key Players

  • Abbott Diagnostics
  • AccuraGen Inc
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Molecular MD
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Oxford Nanopore Technologies
  • Perkin Elmer
  • Personal Genome Diagnostics
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Quidel
  • Rarecells SAS
  • RareCyte
  • Resolution Biosciences, Inc
  • Roche Molecular Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SRI International
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Trovagene
  • Volition

6. The Global Market for Liquid Biopsy Diagnostics

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Cancer - Overview
    • 6.2.1 Table - Global Market by Cancer
    • 6.2.2 Chart - Global Market by Cancer - Base/Final Year Comparison
    • 6.2.3 Chart - Global Market by Cancer - Base Year
    • 6.2.4 Chart - Global Market by Cancer - End Year
    • 6.2.5 Chart - Global Market by Cancer - Share by Year
    • 6.2.6 Chart - Global Market by Cancer - Segments Growth
  • 6.3 Global Market by Usage - Overview
    • 6.3.1 Table - Global Market by Usage
    • 6.3.2 Chart - Global Market by Usage - Base/Final Year Comparison
    • 6.3.3 Chart - Global Market by Usage - Base Year
    • 6.3.4 Chart - Global Market by Usage - End Year
    • 6.3.5 Chart - Global Market by Usage - Share by Year
    • 6.3.6 Chart - Global Market by Usage - Segments Growth

7. Global Liquid Biopsy Diagnostic Markets - By Cancer

  • 7.1 Breast
    • 7.1.1 Table Breast - by Country
    • 7.1.2 Chart - Breast Growth
  • 7.2 Colorectal
    • 7.2.1 Table Colorectal - by Country
    • 7.2.2 Chart - Colorectal Growth
  • 7.3 Cervical
    • 7.3.1 Table Cervical - by Country
    • 7.3.2 Chart - Cervical Growth
  • 7.4 Lung
    • 7.4.1 Table Lung - by Country
    • 7.4.2 Chart - Lung Growth
  • 7.5 Prostate
    • 7.5.1 Table Prostate - by Country
    • 7.5.2 Chart - Prostate Growth
  • 7.6 Other
    • 7.6.1 Table Other - by Country
    • 7.6.2 Chart - Other Growth

8. Global Liquid Biopsy Diagnostic Markets - by Usage

  • 8.1 Screening
    • 8.1.1 Table Screening - by Country
    • 8.1.2 Chart - Screening Growth
  • 8.2 Diagnostic
    • 8.2.1 Table Diagnostic - by Country
    • 8.2.2 Chart - Diagnostic Growth
  • 8.3 Therapy
    • 8.3.1 Table Therapy - by Country
    • 8.3.2 Chart - Therapy Growth
  • 8.4 Monitor
    • 8.4.1 Table Monitor - by Country
    • 8.4.2 Chart - Monitor Growth

Appendices

  • I. United States Medicare System: 2020 Clinical Laboratory Fees Schedule
  • II. COVID-19 Approved Assays

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
  • Table 2 Market Players by Type
  • Table 3 Biopsy Sites
  • Table 4 Advantages of Liquid Biopsy in Screening Market
  • Table 5 Outlook - Phases of Liquid Biopsy Adoption by Year
  • Table 6 Five Factors Driving Growth
  • Table 7 Factors Limiting Growth
  • Table 8 Key Diagnostic Laboratory Technology Trends
  • Table 9 Next Generation Sequencing Technologies - Speed and Cost
  • Table 10 - Global Market by Region
  • Table 11 Global Market by Cancer
  • Table 12 Global Market by Usage
  • Table 13 Breast by Country
  • Table 14 Colorectal by Country
  • Table 15 Cervical by Country
  • Table 16 Lung by Country
  • Table 17 Prostate by Country
  • Table 18 Other by Country
  • Table 19 Screening by Country
  • Table 20 Diagnostic by Country
  • Table 21 Therapy by Country
  • Table 22 Monitor by Country
  • Table 23 2020 Clinical Lab Fee Schedule
  • Table 24 COVID -19 Approved Assays

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • Figure 2 Comparison of Liquid Biopsy Classes
  • Figure 3 Characteristics of Different Vesicle Types
  • Figure 4 Percentage of World Population Over 65
  • Figure 5 Global Market Density Chart
  • Figure 6 Global Market by Cancer - Base vs. Final
  • Figure 7 Global Market by Cancer Base Year
  • Figure 8 Global Market by Cancer End Year
  • Figure 9 Cancer Share by Year
  • Figure 10 Cancer Segments Growth
  • Figure 11 Global Market by Usage - Base vs. Final
  • Figure 12 Global Market by Usage Base Year
  • Figure 13 Global Market by Usage End Year
  • Figure 14 Usage Share by Year
  • Figure 15 Usage Segments Growth
  • Figure 16 Breast Growth
  • Figure 17 Colorectal Diagnostics Growth
  • Figure 18 Cervical Growth
  • Figure 19 Lung Growth
  • Figure 20 Prostate Growth
  • Figure 21 Other Growth
  • Figure 22 Screening Growth
  • Figure 23 Diagnostic Growth
  • Figure 24 Therapy Growth
  • Figure 25 Monitor Growth